Real-world study of acalabrutinib for MCL or CLL
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how acalabrutinib works in real-world everyday medical practice for people with MCL or CLL who have already had at least one prior treatment. The goal is to see how well the drug performs outside of a strict research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with MCL or CLL and have already received at least one prior treatment.
- Your doctor has decided that acalabrutinib is a suitable treatment option for you.
- You are not currently participating in another clinical trial that involves treatment.
- If you are a female who could become pregnant, you must use effective birth control during treatment and for 1 week after, and have a negative pregnancy test before starting.
- You have not had your cancer worsen while on a different BTK inhibitor drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether acalabrutinib plus venetoclax can control newly diagnosed chronic lymphocytic leukemia (CLL) in people who are at higher risk of infections or who likely need treatment soon. It aims to see if this combination can improve disease control while keeping patients safe.
This study tests acalabrutinib together with obinutuzumab in people with newly diagnosed chronic lymphocytic leukemia (CLL) to see how well the combination works. It may help by improving control of the cancer, but you’ll be closely monitored for side effects.
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Hear when a new MCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.